Hudes GR - Search Results

1

Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.

Lee HO, Mustafa A, Hudes GR, Kruger WD. Lee HO, et al. Among authors: hudes gr. PLoS One. 2015 Jul 2;10(7):e0131464. doi: 10.1371/journal.pone.0131464. eCollection 2015. PLoS One. 2015. PMID: 26134285 Free PMC article.

2

Serum amino acid levels as a biomarker for renal cell carcinoma.

Mustafa A, Gupta S, Hudes GR, Egleston BL, Uzzo RG, Kruger WD. Mustafa A, et al. Among authors: hudes gr. J Urol. 2011 Oct;186(4):1206-12. doi: 10.1016/j.juro.2011.05.085. Epub 2011 Aug 17. J Urol. 2011. PMID: 21849193 Free PMC article.

3

Targeting mTOR in renal cell carcinoma.

Hudes GR. Hudes GR. Cancer. 2009 May 15;115(10 Suppl):2313-20. doi: 10.1002/cncr.24239. Cancer. 2009. PMID: 19402072 Free article. Review.

4

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB. Plimack ER, et al. Among authors: hudes gr. Oncologist. 2014 Apr;19(4):354-5. doi: 10.1634/theoncologist.2014-0020. Epub 2014 Mar 27. Oncologist. 2014. PMID: 24674872 Free PMC article. Clinical Trial.

5

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.

Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J. Hudes GR, et al. Semin Oncol. 2009 Dec;36 Suppl 3:S26-36. doi: 10.1053/j.seminoncol.2009.10.013. Semin Oncol. 2009. PMID: 19963097 Review.

6

mTOR as a target for therapy of renal cancer.

Hudes GR. Hudes GR. Clin Adv Hematol Oncol. 2007 Oct;5(10):772-4. Clin Adv Hematol Oncol. 2007. PMID: 17998894 No abstract available.

7

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS. MacFarlane AW 4th, et al. Among authors: hudes gr. Cancer Immunol Res. 2014 Apr;2(4):320-31. doi: 10.1158/2326-6066.CIR-13-0133. Epub 2013 Nov 25. Cancer Immunol Res. 2014. PMID: 24764579 Free PMC article.

8

Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents.

Ranganathan S, Dexter DW, Benetatos CA, Hudes GR. Ranganathan S, et al. Among authors: hudes gr. Biochim Biophys Acta. 1998 Jan 21;1395(2):237-45. doi: 10.1016/s0167-4781(97)00168-1. Biochim Biophys Acta. 1998. PMID: 9473684

9

Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.

Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. Haas NB, et al. Among authors: hudes gr. Clin Cancer Res. 2003 Jan;9(1):109-14. Clin Cancer Res. 2003. PMID: 12538458 Clinical Trial.

10

Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.

Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Ranganathan S, et al. Among authors: hudes gr. Cancer Res. 1996 Jun 1;56(11):2584-9. Cancer Res. 1996. PMID: 8653701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page